Ocuphire Pharma Results

Ocuphire Overview Two Late-Stage Clinical Assets Addressing Unmet Needs in Multiple Large Markets Nyxol 12 Completed Phase 1, Phase 2, and Phase 3 Trials Ocuphire Refractive Novel a1/a2 Blocker 505(b)(2) >650 Subjects Dosed Reversal of Mydriasis Presbyopia Night Vision Disturbances Exposure in Humans 28 Days Prevalence (US) ~100 M ~128 M NDA-Filing Ready ~36 M Patent Coverage 2034+ Development Milestone 2 Phase 3 Positive Data & Ped P3 Phase 2 Positive Data Single & Combo 1st Phase 3 Positive Data APX3330 11 Completed Phase 1 and Phase 2 Trials Source: Eisai and Apexian Data; GlobalData Market Research Report, 2020; Company Estimates for US Market Size; Ocuphire internal estimates Retina Oral REF-1 Inhibitor New Chemical Entity >340 Subjects Dosed Diabetic Retinopathy Diabetic Macular Edema Exposure in Humans 365 Days Prevalence (US) ~8 M Phase 2b Data 4Q22 ~2.4 M Patent Coverage 2034+ Development Milestone Phase 2b Last Patient Last Visit Completed Aug 22 7

View entire presentation